<SEC-DOCUMENT>0001104659-16-152602.txt : 20161027
<SEC-HEADER>0001104659-16-152602.hdr.sgml : 20161027
<ACCEPTANCE-DATETIME>20161027162901
ACCESSION NUMBER:		0001104659-16-152602
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20161024
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20161027
DATE AS OF CHANGE:		20161027

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Adaptimmune Therapeutics PLC
		CENTRAL INDEX KEY:			0001621227
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37368
		FILM NUMBER:		161955859

	BUSINESS ADDRESS:	
		STREET 1:		101 PARK DRIVE
		STREET 2:		MILTON PARK
		CITY:			ABINGDON, OXFORDSHIRE
		STATE:			X0
		ZIP:			OX14 4RY
		BUSINESS PHONE:		44 1235 430000

	MAIL ADDRESS:	
		STREET 1:		101 PARK DRIVE
		STREET 2:		MILTON PARK
		CITY:			ABINGDON, OXFORDSHIRE
		STATE:			X0
		ZIP:			OX14 4RY

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Adaptimmune Ltd
		DATE OF NAME CHANGE:	20141001
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a16-20493_18k.htm
<DESCRIPTION>8-K
<TEXT>


<html>
<head>




  </head>
<body link=blue lang="EN-US">
<div style="font-family:Times New Roman;">
<div style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 3.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">UNITED STATES <br> SECURITIES AND EXCHANGE COMMISSION</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Washington, D.C. 20549</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">FORM&nbsp;8-K</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">Current Report</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">Pursuant to Section&nbsp;13 or 15(d)&nbsp;of</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">the Securities Exchange Act of 1934</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date of Report (Date of earliest event reported):<b> October&nbsp;24, 2016</b></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">ADAPTIMMUNE THERAPEUTICS PLC</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Exact name of registrant as specified in its charter)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">England   and Wales</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1-37368</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Not   Applicable</font></b></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(State or other   jurisdiction of<br>   incorporation)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Commission File Number)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(IRS Employer   Identification No.)</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">101 Park Drive, Milton Park</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Abingdon, Oxfordshire OX14 4RY</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">United Kingdom</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Address of principal executive offices, including zip code)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(44) 1235 430000</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Registrant&#146;s telephone number, including area code)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Check the appropriate box below if the Form&nbsp;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</p>
<p style="margin:0in 0in .0001pt 3.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>
<p style="margin:0in 0in .0001pt 3.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Pre-commencement communications pursuant to Rule&nbsp;14d-2(b)&nbsp;under the Exchange Act (17 CFR 240.14d-2(b))</p>
<p style="margin:0in 0in .0001pt 3.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Pre-commencement communications pursuant to Rule&nbsp;13e-4(c)&nbsp;under the Exchange Act (17 CFR 240.13e-4(c))</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="border-bottom:solid windowtext 3.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\109512\16-20493-1\task8144859\20493-1-ba.htm',USER='109512',CD='Oct 27 00:17 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 1.01.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Entry into a Material Definitive Agreement.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On October&nbsp;27, 2016, Adaptimmune Therapeutics plc (the &#147;Company&#148;) entered into a clinical trial collaboration agreement with Merck&nbsp;&amp; Co.,&nbsp;Inc., Kenilworth, NJ, USA (known as MSD outside the US and Canada), for the assessment of Adaptimmune&#146;s NY-ESO SPEAR&#174; (Specific Peptide Enhanced Affinity Receptor) T-cell therapy in combination with MSD&#146;s anti-programmed death-1 (PD-1) inhibitor</font>, KEYTRUDA&#174; (pembrolizumab), in patients with multiple myeloma (the &#147;Collaboration Agreement&#148;). The study will evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the combination, and is planned for initiation in first half of 2017.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company also confirms that on October&nbsp;24, 2016 it entered into a lease with MEPC Milton Park of a 67,100 square foot building at Milton Park, Oxfordshire, U.K. for 25 years, with break options, pursuant to an agreement for lease between the Company and MEPC Milton Park dated September&nbsp;16, 2015. The new building comprises laboratory and office space and will accommodate the Company&#146;s research and development and U.K. corporate operations.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 8.01.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Other Events.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On October&nbsp;27, 2016, the Company issued a press release announcing the Collaboration Agreement. &nbsp;A copy of the press release is furnished as Exhibit&nbsp;99.1 to this report.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The information in Item&nbsp;8.01 of this Form&nbsp;8-K (including the attached Exhibit&nbsp;99.1) shall not be deemed &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing, regardless of any general incorporation language in any such filing, unless the Company expressly sets forth in such filing that such information is to be considered &#147;filed&#148; or incorporated by reference therein.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 9.01</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Financial Statements and Exhibits.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)&nbsp; Exhibits.&#160; The following exhibit is furnished as part of this Report on Form&nbsp;8-K:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="93%" style="border-collapse:collapse;margin-left:.5in;">
<tr>
<td width="10%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Exhibit&nbsp;No.</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="86%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:86.78%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Description&nbsp;of&nbsp;Exhibit</font></b></p>    </td>   </tr>
<tr>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.7%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.7%;">
<p style="margin:0in 0in .0001pt .2in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.1</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Press Release dated   October&nbsp;27, 2016.</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">2<a name="PB_2_001123_6763"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\109512\16-20493-1\task8144859\20493-1-ba.htm',USER='109512',CD='Oct 27 00:17 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SIGNATURES</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:49.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ADAPTIMMUNE   THERAPEUTICS PLC</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:49.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="44%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:44.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date: October&nbsp;27,   2016</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="44%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:44.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Margaret Henry</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="37%" valign="top" style="padding:0in 0in 0in 0in;width:37.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Margaret Henry</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="37%" valign="top" style="padding:0in 0in 0in 0in;width:37.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Corporate Secretary</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">3<a name="PB_3_001320_7056"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\109512\16-20493-1\task8144859\20493-1-ba.htm',USER='109512',CD='Oct 27 00:17 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;Index</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="10%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Exhibit&nbsp;No.</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="87%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:87.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Description&nbsp;of&nbsp;Exhibit</font></b></p>    </td>   </tr>
<tr>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="87%" valign="top" style="padding:0in 0in 0in 0in;width:87.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.1</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="87%" valign="top" style="padding:0in 0in 0in 0in;width:87.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Press Release dated   October&nbsp;27, 2016</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">4<a name="PB_4_001413_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='4',FILE='C:\JMS\109512\16-20493-1\task8144859\20493-1-ba.htm',USER='109512',CD='Oct 27 00:17 2016' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a16-20493_1ex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>


<html>
<head>



  </head>
<body link=blue lang="EN-US">
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 99.1</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman"><img width="338" height="69" src="g204931mmi001.gif"></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Adaptimmune Announces Collaboration with MSD to Evaluate KEYTRUDA</font></b><b><font size="1" style="font-size:6.5pt;font-weight:bold;position:relative;top:-3.0pt;">&#174;</font></b><b>&#160;(pembrolizumab) in Combination with NY-ESO SPEAR</b><b><font size="1" style="font-size:6.5pt;font-weight:bold;position:relative;top:-3.0pt;">&#174;</font></b><b>&#160;T-Cell Therapy in Multiple Myeloma</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">PHILADELPHIA, Pa. and OXFORD, UK., October&nbsp;27, 2016 &#151; Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced that it has entered into a clinical trial collaboration agreement with Merck&nbsp;&amp; Co.,&nbsp;Inc., Kenilworth, NJ, USA (known as MSD outside the US and Canada), for the assessment of Adaptimmune&#146;s NY-ESO SPEAR</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font>&#160;(Specific Peptide Enhanced Affinity Receptor) T-cell therapy in combination with MSD&#146;s anti-programmed death-1 (PD-1) inhibitor, KEYTRUDA<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font>&#160;(pembrolizumab), in patients with multiple myeloma. The study will evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the combination, and is planned for initiation in 1H 2017.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Adaptimmune&#146;s SPEAR T-cell candidates are novel cancer immunotherapies that have been engineered to target and destroy cancer cells. Its NY-ESO SPEAR T-cell therapy has previously been evaluated in multiple myeloma in a single agent Phase I/II trial in which 20 out of 22 patients (91 percent) experienced a response at day 100 post autologous stem cell transplant. KEYTRUDA is a humanized monoclonal antibody that works by increasing the ability of the body&#146;s immune system to help detect and fight tumor cells.&#160; KEYTRUDA blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells. Blocking this interaction is reported to enable T-cell activation and potentiates antitumor activity.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;In initial single-agent studies of our NY-ESO SPEAR T-cell therapy in patients with advanced myeloma in the context of stem cell transplantation, we have seen encouraging evidence of antitumor effect, safe administration and prolonged persistence of transduced cells,&#148; said Rafael Amado, Adaptimmune&#146;s chief medical officer. &#147;KEYTRUDA has shown preliminary evidence of activity in multiple myeloma, and there is preclinical evidence to support the view that the combination of NY-ESO SPEAR T-cell therapy and anti-PD1 therapy may lead to meaningful anti-tumor activity. We look forward to evaluating our therapy alone and in combination with KEYTRUDA in a randomized trial of patients with multiple myeloma who are refractory or have relapsed with standard therapy.&#148;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The agreement is between Adaptimmune and Merck&nbsp;&amp; Co.,&nbsp;Inc., Kenilworth, NJ, USA, through a subsidiary. Under the agreement, the trial will be sponsored by Adaptimmune. The agreement also includes provision for potential expansion to include Phase III registration studies in the same indication. Additional details were not disclosed.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">About Multiple Myeloma</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Multiple myeloma is a cancer formed by malignant plasma cells. Normal plasma cells are found in the bone marrow and are an important part of the immune system, which is made up of several types of cells that work together to fight infections and other diseases. Multiple myeloma is characterized by several features, including low blood counts, bone and calcium problems, infections, kidney problems, monoclonal gammopathy, and others; and by the proliferation of these plasma cells within bone marrow. The American Cancer Society estimates that approximately 30,300 new cases will be diagnosed in the United States in 2016. </font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\108183\16-20493-1\task8145031\20493-1-mm.htm',USER='108183',CD='Oct 27 01:21 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Average five-year survival rates are estimated to be approximately 45 percent with survival rates depending on factors such as age, stage of diagnosis and suitability for auto-SCT, which is used as part of the treatment for eligible patients with multiple myeloma. Despite recent therapeutic advances, multiple myeloma remains an incurable but treatable cancer. Patients are typically treated with repeat rounds of combination therapy with the time intervals to relapse becoming shorter with each successive line of therapy. The majority of patients eventually have a relapse which cannot be further treated.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">About Adaptimmune&#146;s TCR Technology</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Adaptimmune&#146;s proprietary SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell receptor (TCR) technology enables the company to genetically optimize TCRs, equipping them to recognize cancer antigens that are presented in small quantities on the surface of a cancer cell, whether of intracellular or extracellular origin, thus initiating cell death. The company&#146;s differentiated, proprietary technology allows it to reliably generate parental TCRs to naturally presented targets, affinity optimize its TCRs to bind cancer proteins from solid and hematologic cancers that are generally unavailable to naturally occurring TCRs, and to significantly reduce the risk of side effects resulting from off-target binding of healthy tissues.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">About Adaptimmune</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Adaptimmune is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its SPEAR</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font>&#160;(Specific Peptide Enhanced Affinity Receptor) T-cell platform. Established in 2008, the company aims to utilize the body&#146;s own machinery - the T-cell - to target and destroy cancer cells by using engineered, increased affinity TCRs as a means of strengthening natural patient T-cell responses. Adaptimmune&#146;s lead program is a SPEAR T-cell therapy targeting the NY-ESO cancer antigen. Its NY-ESO SPEAR T-cell therapy has demonstrated signs of efficacy and tolerability in Phase 1/2 trials in solid tumors and in hematologic cancer types, including synovial sarcoma and multiple myeloma. Adaptimmune has a strategic collaboration and licensing agreement with GlaxoSmithKline for the development and commercialization of the NY-ESO TCR program. In addition, Adaptimmune has a number of proprietary programs. These include SPEAR T-cell therapies targeting the MAGE-A10 and AFP cancer antigens, which both have open INDs, and a further SPEAR T-cell therapy targeting the MAGE-A4 cancer antigen that is in pre-clinical phase with IND acceptance targeted for 2017. The company has identified over 30 intracellular target peptides preferentially expressed in cancer cells and is currently progressing 12 through unpartnered research programs. Adaptimmune has over 250 employees and is located in Oxfordshire, U.K. and Philadelphia, USA. For more information: http://www.adaptimmune.com</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Forward-Looking Statements</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This release contains &#147;forward-looking statements&#148; within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Quarterly Report on Form&nbsp;10-Q filed with the Securities and Exchange Commission (SEC) on August&nbsp;8, 2016, and our other SEC filings. </font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\108183\16-20493-1\task8145031\20493-1-mm.htm',USER='108183',CD='Oct 27 01:21 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">KEYTRUDA</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font>&#160;is a registered trademark of Merck Sharp&nbsp;&amp; Dohme Corp., a subsidiary of Merck&nbsp;&amp; Co.,&nbsp;Inc., Kenilworth, NJ, USA.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Adaptimmune Contacts</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Will Roberts</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Vice President,&nbsp;Investor Relations</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">T:&#160; (215) 825-9306</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">E: will.roberts@adaptimmune.com</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Juli P. Miller, Ph.D.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Associate Director,&nbsp;Investor Relations</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">T:&#160; (215) 825-9310</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">E: juli.miller@adaptimmune.com</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Margaret Henry</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Head of PR</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">T: +44 (0)1235 430036</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Mob: +44 (0)7710 304249</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">E: margaret.henry@adaptimmune.com</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\108183\16-20493-1\task8145031\20493-1-mm.htm',USER='108183',CD='Oct 27 01:21 2016' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g204931mmi001.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g204931mmi001.gif
M1TE&.#=A4@%% '<  "'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "P
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MI0"""V9M;.@@" Q9'&(Q:JC   >>BQ@2=+  (D^8 QDAR!C! <Z!#B)PB.A
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..B2>FN&*++\8XX8   #L!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
